Northwest Biotherapeutics, Inc.
NWBOW
NWBOW was delisted on the 16th of December, 2016.
1 hedge funds and large institutions have $0 invested in Northwest Biotherapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
100% less capital invested
Capital invested by funds: $3K → $0 (-$3K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| – | -$2.33K | -801 | -83% |
|
NWBOW Hedge Fund Activity: Q4 2015 in Review
1 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. (NWBOW) for Q4 2015, worth a combined $0 — down 100% from $3K a quarter earlier.
Fund positioning in NWBOW was balanced in Q4 2015: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $2.33K.
- 1 institutional investor held Northwest Biotherapeutics, Inc. (NWBOW) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $0 of Northwest Biotherapeutics, Inc. stock for Q4 2015, down 100% quarter-over-quarter.
- 0 funds opened new Northwest Biotherapeutics, Inc. positions in Q4 2015 and 0 closed out.
- The largest Northwest Biotherapeutics, Inc. seller in Q4 2015 was UBS Group, an estimated $2.33K sold.
Based on aggregated 13F filings for Q4 2015.